Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.70B | 1.08B | 820.22M | 625.49M | 391.00M | Gross Profit |
1.02B | 492.74M | 363.97M | 307.07M | 187.38M | EBIT |
-222.29M | -446.25M | -541.04M | -468.17M | -216.28M | EBITDA |
-148.08M | -383.28M | -520.80M | -451.54M | -205.95M | Net Income Common Stockholders |
-190.43M | -434.80M | -547.80M | -471.72M | -229.74M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
968.28M | 878.98M | 898.31M | 914.28M | 737.27M | Total Assets |
1.66B | 1.44B | 1.39B | 1.24B | 932.15M | Total Debt |
187.12M | 441.99M | 438.58M | 391.48M | 273.79M | Net Debt |
-758.47M | -200.10M | -27.43M | 307.10M | 225.13M | Total Liabilities |
465.31M | 676.37M | 688.73M | 583.18M | 445.92M | Stockholders Equity |
1.20B | 765.33M | 705.74M | 653.30M | 486.24M |
Cash Flow | Free Cash Flow | |||
69.24M | -286.15M | -479.20M | -376.27M | -202.12M | Operating Cash Flow |
135.66M | -246.96M | -431.50M | -335.24M | -182.51M | Investing Cash Flow |
137.62M | 168.50M | 330.34M | -205.19M | -331.46M | Financing Cash Flow |
30.20M | 254.46M | 482.64M | 576.19M | 500.85M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $18.94B | 22.26 | 13.24% | 1.83% | 6.70% | 2.56% | |
67 Neutral | $18.75B | ― | -19.42% | ― | 56.75% | 59.77% | |
66 Neutral | $8.27B | 102.99 | 2.27% | ― | 0.66% | -75.89% | |
53 Neutral | $8.23B | ― | -37.09% | ― | 10.37% | -389.98% | |
49 Neutral | $12.10B | ― | -30.11% | ― | -2.93% | -4.69% | |
49 Neutral | $5.19B | ― | -4584.47% | ― | 31.04% | 16.91% | |
48 Neutral | $6.36B | 1.09 | -49.92% | 2.63% | 17.17% | 0.95% |
Natera, Inc. has announced the appointment of Monica Bertagnolli to its Board of Directors, effective March 6, 2025, increasing the board size from ten to eleven members. Dr. Bertagnolli, who previously served on the board from November 2020 to August 2022, will serve as a Class III director with a term expiring in 2027. Her appointment follows her tenure as Director of the National Cancer Institute, and she is recognized as an independent director under the Securities Act of 1933 and Nasdaq listing standards. Dr. Bertagnolli will also join the Nominating, Corporate Governance and Compliance Committee and will receive compensation similar to other non-employee directors. The company has also entered into an Indemnification Agreement with her, ensuring legal protection related to her service.